Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma.
Tuomainen K, Hyytiäinen A, Al-Samadi A, Ianevski P, Ianevski A, Potdar S, Turunen L, Saarela J, Kuznetsov S, Wahbi W, Risteli M, Mäkitie A, Monni O, Salo T. Tuomainen K, et al. Among authors: potdar s. Sci Rep. 2021 Jul 20;11(1):14755. doi: 10.1038/s41598-021-94259-5. Sci Rep. 2021. PMID: 34285300 Free PMC article.
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
Bogacheva MS, Kuivanen S, Potdar S, Hassinen A, Huuskonen S, Pöhner I, Luck TJ, Turunen L, Feodoroff M, Szirovicza L, Savijoki K, Saarela J, Tammela P, Paavolainen L, Poso A, Varjosalo M, Kallioniemi O, Pietiäinen V, Vapalahti O. Bogacheva MS, et al. Among authors: potdar s. Antiviral Res. 2024 Mar;223:105813. doi: 10.1016/j.antiviral.2024.105813. Epub 2024 Jan 24. Antiviral Res. 2024. PMID: 38272320 Free article.
Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.
Pietiäinen V, Polso M, Migh E, Guckelsberger C, Harmati M, Diosdi A, Turunen L, Hassinen A, Potdar S, Koponen A, Sebestyen EG, Kovacs F, Kriston A, Hollandi R, Burian K, Terhes G, Visnyovszki A, Fodor E, Lacza Z, Kantele A, Kolehmainen P, Kakkola L, Strandin T, Levanov L, Kallioniemi O, Kemeny L, Julkunen I, Vapalahti O, Buzas K, Paavolainen L, Horvath P, Hepojoki J. Pietiäinen V, et al. Among authors: potdar s. Cell Rep Methods. 2023 Aug 22;3(8):100565. doi: 10.1016/j.crmeth.2023.100565. eCollection 2023 Aug 28. Cell Rep Methods. 2023. PMID: 37671026 Free PMC article.
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, Kim D, Potdar S, Wolf M, Lotfi K, Aittokallio T, Wennerberg K, Porkka K, Mustjoki S. Adnan Awad S, et al. Among authors: potdar s. Cell Rep Med. 2024 Apr 10:101521. doi: 10.1016/j.xcrm.2024.101521. Online ahead of print. Cell Rep Med. 2024. PMID: 38653245 Free article.
Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.
Roering P, Siddiqui A, Heuser VD, Potdar S, Mikkonen P, Oikkonen J, Li Y, Pikkusaari S, Wennerberg K, Hynninen J, Grenman S, Huhtinen K, Auranen A, Carpén O, Kaipio K. Roering P, et al. Among authors: potdar s. Front Oncol. 2022 Aug 23;12:954430. doi: 10.3389/fonc.2022.954430. eCollection 2022. Front Oncol. 2022. PMID: 36081565 Free PMC article.
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K. Pietarinen PO, et al. Among authors: potdar s. Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146. Oncotarget. 2017. PMID: 28186983 Free PMC article.
101 results